IRIS
AURIEMMA, RENATA SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.829
NA - Nord America 4.217
EU - Europa 3.018
SA - Sud America 608
AF - Africa 115
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 12.796
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.046
SG - Singapore 2.151
RU - Federazione Russa 1.501
CN - Cina 980
VN - Vietnam 847
BR - Brasile 467
HK - Hong Kong 398
IT - Italia 378
DE - Germania 236
FR - Francia 163
SE - Svezia 155
FI - Finlandia 138
NL - Olanda 110
CA - Canada 97
GB - Regno Unito 81
IE - Irlanda 74
IN - India 72
AR - Argentina 63
UA - Ucraina 63
JP - Giappone 56
BD - Bangladesh 55
MX - Messico 44
KR - Corea 37
IQ - Iraq 33
TH - Thailandia 27
ZA - Sudafrica 26
CI - Costa d'Avorio 25
EC - Ecuador 24
PL - Polonia 23
TR - Turchia 21
ES - Italia 20
PH - Filippine 20
CO - Colombia 16
KE - Kenya 16
PK - Pakistan 16
TW - Taiwan 16
AT - Austria 14
ID - Indonesia 14
IR - Iran 13
VE - Venezuela 12
EG - Egitto 11
LT - Lituania 10
UZ - Uzbekistan 10
BE - Belgio 9
MA - Marocco 9
CL - Cile 8
IL - Israele 8
PY - Paraguay 8
CZ - Repubblica Ceca 7
OM - Oman 7
AE - Emirati Arabi Uniti 6
JM - Giamaica 6
JO - Giordania 6
CH - Svizzera 5
DO - Repubblica Dominicana 5
DZ - Algeria 5
LB - Libano 5
SA - Arabia Saudita 5
TN - Tunisia 5
UY - Uruguay 5
PT - Portogallo 4
RO - Romania 4
SY - Repubblica araba siriana 4
AL - Albania 3
AZ - Azerbaigian 3
PA - Panama 3
PE - Perù 3
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BO - Bolivia 2
BS - Bahamas 2
EE - Estonia 2
ET - Etiopia 2
GA - Gabon 2
GM - Gambi 2
GT - Guatemala 2
HN - Honduras 2
HU - Ungheria 2
KG - Kirghizistan 2
LC - Santa Lucia 2
LK - Sri Lanka 2
NZ - Nuova Zelanda 2
PF - Polinesia Francese 2
QA - Qatar 2
RW - Ruanda 2
SN - Senegal 2
TL - Timor Orientale 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AU - Australia 1
BB - Barbados 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
CV - Capo Verde 1
Totale 12.769
Salva come PNG Salva come JPEG
Città #
Singapore 1.029
San Jose 965
Hong Kong 387
Moscow 381
Chandler 369
Ashburn 299
Beijing 298
Ho Chi Minh City 268
Hanoi 195
Hefei 166
Santa Clara 146
The Dalles 144
Naples 123
Munich 103
Lauterbourg 101
Millbury 98
Amsterdam 93
Los Angeles 93
Princeton 72
Jacksonville 71
Nanjing 59
Boston 52
New York 51
Wilmington 51
Tokyo 48
São Paulo 45
Redondo Beach 43
Buffalo 42
Da Nang 38
Helsinki 38
Ottawa 37
Frankfurt am Main 36
Napoli 36
Seattle 36
Dallas 35
Woodbridge 32
Turku 31
Orem 29
Des Moines 28
Seoul 27
Houston 24
Montreal 24
Chicago 23
San Francisco 22
Falls Church 21
Haiphong 21
Falkenstein 20
Mexico City 20
Warsaw 20
Hebei 19
Phoenix 18
Toronto 18
Denver 17
Nairobi 16
Nanchang 16
Rome 15
Shenyang 15
Stockholm 15
Baghdad 14
Lawrence 14
Nuremberg 14
Dublin 13
Rio de Janeiro 13
Ann Arbor 12
Atlanta 12
Changsha 12
Johannesburg 12
London 12
Quito 12
Ardabil 11
Biên Hòa 11
Council Bluffs 11
Hải Dương 11
Jiaxing 11
Manchester 11
Shanghai 11
Ankara 10
Bangkok 10
Boydton 10
Brooklyn 10
Curitiba 10
Dhaka 10
Guangzhou 10
Tianjin 10
Augusta 9
Kronberg 9
Poplar 9
Porto Alegre 9
San Mateo 9
Thái Nguyên 9
Boardman 8
Bologna 8
Can Tho 8
Charlotte 8
Mumbai 8
Salvador 8
Tashkent 8
Brussels 7
Chennai 7
Joinville 7
Totale 6.967
Salva come PNG Salva come JPEG
Nome #
Medical consequences of acromegaly: what are the effects of biochemical control? 222
Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age 178
Effect of the acute administration of the Dopamine Agonist Cabergoline on glucose tolerance and Insuline Sensitivity in patient with obesity. 176
The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients 169
Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. 161
Bisphenol A: An emerging threat to female fertility 160
Long-term high-dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial 157
Circulating myomiRNAs as biomarkers in patients with Cushing's syndrome 156
The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. 152
Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: A retrospective, comparative, head-to-head study 150
The spectrum of cardiac abnormalities in patients with acromegaly: results from a case-control cardiac magnetic resonance study 148
Hypertension in acromegaly and in the normal population: prevalence and determinants 148
Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. 148
Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly 147
The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma 147
The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center. 143
Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors. 142
Acromegaly and the cardiovascular system 142
Severe systemic complications of acromegaly 141
First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group 139
Impact of Somatostatin Analogs vs. Surgery on glucose metabolism in acromegaly: Results of a 5 years observational, open, prospective study 138
New perspectives in the medical treatment of acromegaly 138
Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit 138
Erratum to: The treatment with pasireotide in Cushing’s disease: effects of long–term treatment on tumor mass in the experience of a single center (Endocrine, (2015), 50, (725-740) DOI 10.1007/s12020-015-0557-2) 138
Adverse events associated with somatostatin analogs in acromegaly. 137
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance 137
Fertility in Acromegaly: a single center experience on female patients during active disease and after disease remission 134
The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission. 133
The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology 133
Effect of Chronic Cabergoline Treatment and Testosterone Replacement on Metabolism in Male Patients with Prolactinomas 132
Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly 131
An evaluation of patients with hyperprolactinemia: have dynamic tests had their day? 131
Effect of Cabergoline on Metabolism in Prolactinomas. 131
Mediterranean Diet: What Are the Consequences for Menopause? 130
Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. 130
The Vaginal Microbiome: A Long Urogenital Colonization Throughout Woman Life 130
Growth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects. 128
Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma 126
Approach to the Patient with Prolactinoma 125
Cabergoline counteracts adipose and skeletal muscle lipid accumulation: A novel therapeutic approach to obesity? 124
Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting 121
Somatostatin analogs in the clinical management of pituitary neoplasms 119
Cardiovascular disease in Cushing's syndrome: heart versus vasculature. 118
Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. 117
Effects of initial therapy for five years with somatostatin analogs foracromegaly on growth hormone and insulin-like growth factor-I levels, tumorshrinkage, and cardiovascular disease: a prospective study. 117
Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. 117
Global psychological assessment with the evaluation of life and sleep quality and sexual and cognitive function in a large number of patients with acromegaly: a cross-sectional study 116
A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients 116
Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment 115
Metabolic effects of prolactin 114
Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center 112
The environment and male reproductive system: the potential role and underlying mechanisms of cadmium in testis cancer 111
Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study 111
Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study 111
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms 110
Early Left Ventricular Diastolic Dysfunction in Females with Chronic Hyperprolactinemia: A Doppler Echocardiographic Study 109
PER2 expression and cellular localization play a critical role in tumor aggressiveness and drug resistance in an in vitro model of hepatocellular carcinoma 109
Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients 109
Investigational drugs for the treatment of acromegaly: new agents to transform therapy 108
Treatment with GH receptor antagonist in acromegaly:effect on cardiac arrhythmias. 108
Prevalence of the Metabolic Syndrome in moderately-severely obese subjects with and without Growth Hormone Deficiency. 108
Risk Assessment of Diabetes Mellitus during and after Pregnancy in Women with Prolactinomas 107
Cardiometabolic effects of hypoprolactinemia 107
Metabolic syndrome in the era of COVID-19 outbreak: impact of lockdown on cardiometabolic health 107
Glycometabolic control in Acromegalic patients with Diabetes: a study of the effects of different treatments for GH excess and for hyperglycaemia. 106
Efficacy and tolerability of treatment with pegvisomant in acromegaly: An overview of literature 105
Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy 104
The role of somatostatin receptors in the medical treatment of acromegaly 104
Erratum to: Pituitary tumors and pregnancy: The interplay between a pathologic condition and a physiologic status (Journal of Endocrinological Investigation (2014) 37, (99-112) DOI: 10.1007/s40618-013-0019-8) 104
Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance 103
The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs 102
Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). 102
The safety of treatments for prolactinomas 102
Hyperprolactinemia after menopause: Diagnosis and management 102
TREATMENT WITH GROWTH HORMONE RECEPTOR ANTAGONIST IN ACROMEGALY: EFFECT ON CARDIAC ARRHYTHMIAS. 101
Increased risk of osteoporosis in postmenopausal women with type 2 diabetes mellitus: a three-year longitudinal study with phalangeal QUS measurements 101
Prolactin effects on the pathogenesis of diabetes mellitus 100
Acromegaly and changes in growth parameters: A focus on cardiovascular,metabolic, respiratory abnormalities, malignancies, and bone alterations 99
Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly 98
Microalbuminuria in insulin sensitivity in patients with growth hormone-secreting pituitary tumor 97
Pituitary carcinomas. 97
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. 96
Glucose abnormalities associated to prolactin secreting pituitary adenomas 96
Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs 93
Clinical and genetic characterization of pituitary gigantism: An international collaborative study in 208 patients 93
Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas 93
Diabetes mellitus, vaginal microbiome and sexual function: Outcomes in postmenopausal women 91
Effects of the metabolic syndrome (METS) on gonadal function and sperm parameters in acromegalic patients: a retrospective analisys 91
Clinical Case 1 86
Different effect of acute administration of the dopamine agonist cabergoline on glucose tolerance and insulin sensitivity in obese pateints in relation to GH status. 84
Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities 84
Dopamine Agonists: From the 1970s to Today 83
Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience 82
Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. 82
Evaluation of the retinal nerve fibre layer and ganglion cell complex thickness in pituitary macroadenomas without chiasmal compression. 80
Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study. 77
Low prolactin level identifies hypoactive sexual desire disorder women with a reduced inhibition profile 75
Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-monthstudy. 74
Probiotics and Prebiotics: Any Role in Menopause-Related Diseases? 73
Cushing, acromegaly, GH deficiency and tendons 70
Totale 11.797
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.522
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.522
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202165 0 0 0 0 0 0 0 0 0 0 60 5
2021/2022579 10 0 0 3 16 81 12 19 85 35 115 203
2022/2023819 97 89 21 66 97 90 4 69 144 98 34 10
2023/2024512 22 87 60 55 26 41 13 61 9 10 76 52
2024/20253.297 164 162 43 30 79 175 409 218 178 260 1.271 308
2025/20266.909 721 544 735 591 1.213 285 1.009 343 843 450 175 0
Totale 12.978